31. Deputy John Brady asked the Minister for Health the number of drugs where, following the National Centre for Pharmacoeconomics, NCPE, assessment of the manufacturer's economic dossier on the cost-effectiveness of a drug, including details on all relevant costs and relevant cost offsets including hospitalisation, disease management costs, intravenous antibiotics, adverse events and any additional costs arising in patients not taking a drug, the NCPE found a drug not to be cost-effective; if he will provide this information for each of the past five years with a breakdown of whether additional price reductions were successfully negotiated and agreed upon; and if he will make a statement on the matter. [37860/16]

Summary

31. Deputy John Brady asked the Minister for Health the number of drugs where, following the National Centre for Pharmacoeconomics, NCPE, assessment of the manufacturer's economic dossier on the cost-effectiveness of a drug, including details on all relevant costs and relevant cost offsets including hospitalisation, disease management costs, intravenous antibiotics, adverse events and any additional costs arising in patients not taking a drug, the NCPE found a drug not to be cost-effective; if he will provide this information for each of the past five years with a breakdown of whether additional price reductions were successfully negotiated and agreed upon; and if he will make a statement on the matter. [37860/16]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products Prices

  xml · EN · 1 December 2016

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.